Aileron Therapeutics announced an oral presentation at the European Society for Dermatological Research (ESDR) Annual Meeting, taking place September 28 – October 1, 2022 in Amsterdam. This presentation includes non-clinical data initially presented at the Society for Investigative Dermatology in May 2022 as well as new non-clinical data developed in collaboration with Professor Ralf Paus, M.D., DSc, FRSB and his colleagues at the Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery at the University of Miami Miller School of Medicine. Details of the presentation are as follows: Title: Temporary cell cycle arrest in human scalp hair follicles and their epithelial stem cells by ALRN-6924: A novel strategy to selectively protect p53-wildtype cells against paclitaxel-induced alopecia [Abstract 549] Presenter:  Dr. Ralf Paus; Paus Laboratory, University of Miami Miller School of Medicine Date:   Saturday, October 1, 2022, Time:12:40 – 12:50 p.m. (local time).

Session: Concurrent session #9: Photobiology and Pigmentation. Aileron is currently developing ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells. The company is conducting a Phase 1b clinical trial of ALRN-6924 in patients with p53-mutated breast cancer undergoing either neoadjuvant or adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide, also known as TAC.

Aileron's vision is to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.